Boulder BioScience’s mission is to develop new therapeutic interventions for thrombotic disease. Our immediate goal is to leverage scientific discoveries and new formulation technology into the rapid clinical development of a new API for treating Acute Ischemic Stroke (AIS). Our lead drug candidate delivers a small molecule neuroprotector and immune modulator already supported by pre-clinical safety data and early clinical trial development. The drug candidate has a unique mechanism of action to modulate overactive innate immunity, reducing ischemic and neutrophil-related brain damage in AIS.
The Boulder BioScience leading drug candidate provides a small molecule API achieving sufficient oral bioavailability for AIS treatment. The API is an immune modulator that has already completed extensive pre-clinical safety evaluation and early clinical development. The oral drug candidate has a unique mechanism of action to control unwanted, inflammatory immune system damage to the brain. The API is associated with well-established neuroprotective mechanisms in pre-clinical models of thrombosis, cerebral hypoxia, and brain hemorrhage relevant to AIS. For further information, please email [email protected].